Details for Patent: 9,138,456

Which drugs does patent 9,138,456 protect, and when does it expire?

Patent 9,138,456 protects CUBICIN RF and is included in one NDA.

This patent has forty-seven patent family members in thirty-two countries.

Summary for Patent: 9,138,456

Title:	Lipopeptide compositions and related methods
Abstract:	The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.
Inventor(s):	Sandra O'Connor, Sophie Sun, Gaauri Naik
Assignee:	Cubist Pharmaceuticals LLC
Application Number:	US14/096,346
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,138,456
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Process;

Drugs Protected by US Patent 9,138,456

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	CUBICIN RF	daptomycin	POWDER;INTRAVENOUS	021572-003	Jul 6, 2016		DISCN	Yes	No			Y

International Family Members for US Patent 9,138,456

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	079127
Argentina	123846
Australia	2010321531
Brazil	112012012406
Canada	2781666
Chile	2012001336
Chile	2015002412